Canada
· Delayed Price · Currency is CAD Knight Therapeutics Company Description
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America.
The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms; IPX203 for Parkinson’s disease; Qelbree for attention-deficit hyperactivity disorder; Jornay PM for attention-deficit hyperactivity disorder; and Crexon for Parkinson’s disease.
In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Fibridoner for idiopathic pulmonary fibrosis; Ibsrela for IBS-C; and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease.
Further, the company finances other life science companies; and invests in life sciences venture capital funds.
The company was incorporated in 2013 and is based in Montreal, Canada.
| Country | Canada |
| Founded | 2013 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 745 |
| CEO | Samira Sakhia |
Contact Details
Address: 3400 de Maisonneuve Blvd. W. Montreal, QC H3Z 3B8 Canada | |
| Phone | 514-484-4483 |
| Website | knighttx.com |
Stock Details
| Ticker Symbol | GUD |
| Exchange | Toronto Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| ISIN Number | CA4990531069 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Samira Sakhia BCom, CA, CPA, MBA | President, Chief Executive Officer and Director |
| Jonathan Ross Goodman B.A., L.L.B., M.B.A. | Executive Chairman |
| Arvind Utchanah | Chief Financial Officer |
| Amal Khouri B.Sc., M.B.A. | Chief Business Officer |
| Stephani Saverio | Vice President of Business Development |
| Leopoldo Bosano | Vice-President of Manufacturing and Operations |
| Henrique Dias | Global Vice President of Marketing |
| Susan Caroline Emblem | Global Vice President of Human Resources |
| Jeff Martens | Global Vice President of Commercial |
| Melanie Groleau | Global Vice President of Medical and Clinical |